Ameritas Investment Partners, Inc. Trevi Therapeutics, Inc. Transaction History
Ameritas Investment Partners, Inc.
- $2.98 Billion
- Q4 2024
A detailed history of Ameritas Investment Partners, Inc. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Ameritas Investment Partners, Inc. holds 6,332 shares of TRVI stock, worth $25,074. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,332
Previous 3,438
84.18%
Holding current value
$25,074
Previous $11,000
136.36%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
99Shares Held
59.4MCall Options Held
136KPut Options Held
5.4K-
Nea Management Company, LLC Timonium, MD11.4MShares$45 Million2.9% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA7.38MShares$29.2 Million1.33% of portfolio
-
Rubric Capital Management LP New York, NY5.03MShares$19.9 Million0.47% of portfolio
-
Viking Global Investors LP4.4MShares$17.4 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.51MShares$13.9 Million0.0% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $231M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...